A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis.
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 22 Nov 2017
At a glance
- Drugs CV MG01 (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors CuraVac
- 17 Nov 2017 Planned initiation date changed from 16 Jun 2017 to 1 Jan 2018.
- 17 Nov 2017 Status changed from recruiting to not yet recruiting.
- 20 Jun 2017 Status changed from not yet recruiting to recruiting.